Management of acute kidney injury in consideration of site specificity of renal tubule through the regulation of glucose metabolism
Project/Area Number |
26461208
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Kidney internal medicine
|
Research Institution | Asahikawa Medical College |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
長谷部 直幸 旭川医科大学, 医学部, 教授 (30192272)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 虚血再灌流 / 虚血再灌流障害 / 急性腎障害 / 糖代謝 / アポトーシス / 核酸治療 |
Outline of Final Research Achievements |
These potential therapeutic opportunities utilizing RNAi in vivo are just now being recognized injected from vein, however, the effects of RNAi in vivo injected from renal artery is not well known. It is useful clinically to deliver the vector locally through trans-aortic cathether to reduce adverse effect of siRNA theraphy.Therefore, we chose inhibition of p53 expression following ischemia-reperfusion injury(IR) injected from renal artery as a means to test the efficacy of siRNA in vivo in reducing tubular cell injury and improving renal function.
|
Report
(4 results)
Research Products
(25 results)
-
-
-
-
-
-
[Journal Article] Minimal Change Nephrotic Syndrome Associated with Gefitinib and a Successful Switch to Erlotinib2015
Author(s)
Maruyama K, Chinda J, Kuroshima T, Kabara M, Nakagawa N, Fujino T, Yamamoto Y, Ohsaki Y, Ogawa Y, Hasebe N.
-
Journal Title
Internal Medicine
Volume: 54
Issue: 7
Pages: 823-826
DOI
NAID
ISSN
0918-2918, 1349-7235
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-